The study reported highly significant statistical improvements (p < 0.0001) in stress, anxiety, depression, and migraine-related disability scores, indicating robust effectiveness of MBI in reducing psychological distress and migraine-related dysfunction. Clinical significance was highlighted by defining a ≥25% symptom reduction as a meaningful improvement, aligning with established benchmarks in migraine and psychological research. These results suggest that incorporating MBI alongside pharmacotherapy can lead to substantial improvements in functional outcomes for migraine patients, offering a non-invasive, cost-effective, and scalable adjunct treatment option .

The experimental group, which received both pharmacotherapy and Mindfulness-Based Intervention, showed significantly better outcomes compared to the control group that received only pharmacotherapy. Specifically, 84% of the experimental group demonstrated clinical improvement (defined as ≥25% reduction in symptoms) versus 56% in the control group. The experimental group saw marked reductions in stress, anxiety, depression, and migraine disability scores, while the control group's improvements were milder .

The study utilized figures and graphs to represent participant flow and outcome improvements. For example, Graph 1 depicted clinical improvement percentages, and the y-axis was truncated at 50 for formatting clarity, even though actual values were higher. This decision was made to improve visual clarity, although it resulted in a visual discrepancy, which was acknowledged in discussions to ensure accurate interpretation of the data as 84% for the experimental group and 56% for the control group. Such visual tools are crucial for distilling complex data into easily interpretable formats despite requiring careful attention to details .

Mindfulness-Based Interventions are cost-effective because they typically involve training and practice without the need for expensive equipment or pharmaceuticals, reducing healthcare costs associated with drug use and its side effects. Additionally, mindfulness training can be widely implemented across different settings, making the intervention scalable. Its non-invasive nature and benefits in reducing stress-related components of migraines make it an attractive complement to pharmacotherapy, offering improved patient outcomes without the complications tied to more resource-intensive interventions .

The study was designed as a Randomized Controlled Trial (RCT), which was ethically approved by Geetanjali Medical College & Hospital. To ensure unbiased allocation, participants were randomly assigned to either the control group receiving only pharmacotherapy or the experimental group receiving both pharmacotherapy and Mindfulness-Based Intervention. Randomization was conducted using an Excel-based system where each participant received a random number and sorting determined group placement. Two standardized tools, DASS-21 and MIDAS, were used for measuring stress, anxiety, depression, and migraine-related disability respectively, ensuring a comprehensive evaluation of psychological and headache-related outcomes .

The study included participants aged 18-45 with episodic migraines, excluding those with psychiatric or severe medical disorders. These criteria ensure a homogeneous study population, minimizing confounding factors that might skew results. The age range may be targeted due to the increased prevalence and impact of migraines in this demographic, and excluding severe disorders ensures focus on the intervention's effect on migraines rather than unrelated complications .

Mindfulness-Based Intervention works by enhancing emotional regulation, promoting better coping skills, and reducing stress, which are all factors that contribute to breaking the stress-pain cycle associated with migraines. The intervention helps patients manage and mitigate psychological triggers of migraines, leading to improved overall outcomes when combined with pharmacotherapy. These psychological benefits are supported by the significant reductions in stress, anxiety, and depression observed in patients receiving mindfulness training in the study .

The findings confirm that Mindfulness-Based Interventions, as an adjunct to pharmacotherapy, are consistent with international studies that report improvements in migraine outcomes through mindfulness practices. For instance, studies cited in 'Headache' and 'Pain Medicine' also utilized similar benchmarks for clinical improvement and demonstrated significant benefits. This study contributes new evidence from the Indian population, highlighting mindfulness as a universal therapeutic adjunct across diverse populations and lending further credibility to its global applicability in migraine management .

MIDAS, which stands for Migraine Disability Assessment, measures migraine-related disability by quantifying the number of disability days in the past three months. DASS-21 is used to evaluate psychological distress—specifically stress, anxiety, and depression levels. These tools are utilized together in the study to provide a comprehensive assessment of both the physical and psychological burdens of migraines on patients. Using these measures allows the study to capture the multifaceted impact of migraines and the benefits of the Mindfulness-Based Intervention in both domains .

The research aimed to address whether adding a Mindfulness-Based Intervention (MBI) to pharmacotherapy could improve both psychological and headache-related outcomes among migraine patients. This interest stemmed from the recognition that while pharmacotherapy is beneficial, it may lead to side effects or medication-overuse headaches, and that psychological distress such as stress, anxiety, and depression often accompany migraines and serve as major triggers .